Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeneDx Holdings Corp. (WGS) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. GeneDx is a Delaware‑incorporated company whose Class A common stock trades on The Nasdaq Stock Market under the symbol WGS, with related warrants trading under WGSWW, as noted in its current reports on Form 8‑K.
Investors and analysts can use this page to review current reports on Form 8‑K, which for GeneDx have included announcements of quarterly financial results, updated guidance, and significant corporate events such as board appointments and annual meeting outcomes. These filings offer detail on revenue composition, exome and genome test volumes, margin metrics, cash position, and shareholder voting results, as described in the company’s earnings‑related 8‑K filings.
Because GeneDx positions itself as a global leader in rare disease diagnosis and rare disease genomics, its periodic and current reports are a key source for understanding how its genomic testing business, GeneDx Infinity dataset, and related initiatives translate into financial performance and corporate governance decisions. Filings also disclose information about securities such as its warrants, including listing details and exercise price.
On Stock Titan, SEC documents are paired with AI‑powered summaries that help explain the contents of lengthy filings in accessible language. Users can quickly see the main points from GeneDx’s 8‑K disclosures, and, where applicable, locate information related to quarterly and annual reporting, capital structure, and significant events affecting WGS shareholders. Real‑time updates from EDGAR ensure that new GeneDx filings appear promptly, while AI‑generated highlights make it easier to navigate complex regulatory documents.
GeneDx Holdings Corp. chief executive officer Katherine Stueland reported routine equity compensation activity involving restricted stock units and related tax sales. On April 29, 2026, 3,874 restricted stock units converted into the same number of shares of Class A Common Stock for no cash consideration, increasing her direct holdings.
The filing also shows open-market sales totaling 2,172 shares of Class A Common Stock at prices around the mid‑$60s per share to cover tax withholding obligations from the RSU vesting. A footnote states this was a “sell to cover” transaction and “does not represent a discretionary transaction.” Following these sales, she beneficially owned 93,216 shares of Class A Common Stock, plus RSUs for up to 330,821 additional shares and options to purchase up to 107,610 shares, all vesting under their existing schedules.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. On April 29, 2026, 754 restricted stock units converted into Class A Common Stock, and 392 shares were sold in an open-market transaction to cover tax withholding obligations under a non-discretionary "sell to cover" arrangement. Following these transactions, he beneficially owned 34,942 shares of Class A Common Stock, plus RSUs representing contingent rights to receive up to 92,419 additional shares and options to purchase up to 25,906 shares, all vesting according to their respective schedules.
GeneDx Holdings files its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, describing its clinical genomics business, operations, risks, and regulatory environment.
The report states an aggregate market value of voting common stock held by non-affiliates of $1.66 billion as of June 30, 2025 and notes 29,288,739 shares outstanding as of February 17, 2026. It describes GeneDx’s dataset (over 2.5 million tests, including over 1 million exomes and genomes), commercialization strategy targeting pediatrics, NICU and newborn screening, reliance on key suppliers, FDA LDT regulatory uncertainty, and ongoing research programs such as GUARDIAN.
GeneDx Holdings Corp. is holding its 2026 virtual annual meeting on June 18, 2026 to elect one Class II director, ratify Ernst & Young LLP as auditor, and conduct advisory votes on executive compensation and its voting frequency. The Board supports electing CEO Katherine Stueland as Class II director, ratifying Ernst & Young, approving executive pay, and holding say‑on‑pay votes every year.
The proxy highlights 2025 performance, including revenue of $427.5 million, 41% year‑over‑year growth, exome and genome test revenue of $360.3 million, adjusted gross margin of 71%, and adjusted net income of $41.8 million. Executive pay is structured around base salary, annual cash incentives, and equity awards, with increased use of performance‑based RSUs and new stock ownership and clawback policies.
WGS reported proposed dispositions of Class A Common Stock by an affiliate under Form 144. The filing lists restricted stock units acquired on 05/02/2022 (392 shares), 09/01/2022 (374 shares), 12/09/2022 (1,284 shares) and 04/26/2023 (3,754 shares). The Form 144 shows multiple sales reported during early 2026, including 317 shares on 01/29/2026, 287 shares on 03/02/2026, 6,187 shares on 03/04/2026, 1,280 shares on 03/09/2026, 5,706 shares on 03/16/2026, and 8,818 shares on 03/26/2026. The filing identifies Morgan Stanley Smith Barney as broker and lists NASDAQ as the market.
WGS affiliate reported proposed sales of Class A common stock under Form 144. The filing lists multiple RSU-derived share lots and a series of sales by Katherine Stueland, with individual sale quantities and post-transaction holdings shown for dates in 2026.
The notice records sale dates and share counts; timing and placement details beyond the listed dates are not included.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. He exercised 16,250 restricted stock units, receiving the same number of Class A Common Stock shares for no cash cost. On the same date, he sold 8,818 shares of Class A Common Stock in several open-market transactions at weighted average prices in the low-to-mid $60s per share. According to the disclosure, these sales were executed solely to cover tax withholding obligations from the RSU vesting under a “sell to cover” arrangement and were not discretionary trades. After these transactions, he beneficially owned 34,580 shares of Class A Common Stock, plus RSUs representing contingent rights to receive up to 93,173 additional shares and options to purchase up to 25,906 shares, all vesting over time according to their terms.
GeneDx Holdings Corp. CEO Katherine Stueland exercised 80,000 restricted stock units into Class A common stock and had 46,933 shares sold to cover tax withholding obligations. The sales were executed as non-discretionary “sell to cover” transactions at weighted average prices between approximately $60.93 and $65.61 per share.
After these transactions, she beneficially owned 91,514 shares of Class A common stock and also held restricted stock units representing contingent rights to receive up to 334,695 additional shares, plus options to purchase up to 107,610 shares that vest according to their terms.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity compensation activity involving restricted stock units and related tax sales. She exercised RSUs covering 30,671 shares of Class A Common Stock at no cost as tranches vested on March 15–16. To cover tax withholding obligations from these vestings, she sold 17,179 shares in open-market transactions at weighted average prices in ranges around $75.74 to $78.16 per share pursuant to a sell-to-cover arrangement, which the filing notes was not a discretionary transaction. Following these tax-related sales, she directly owned 58,447 shares of Class A Common Stock and held RSUs representing up to 414,695 additional shares and options to purchase 107,610 shares, all vesting according to their existing terms.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity. On March 15–16, 2026, he exercised restricted stock units that converted into a total of 11,012 shares of Class A Common Stock at no cost.
On March 16, he then sold 5,706 shares of Class A Common Stock in multiple open-market transactions at weighted average prices in the mid‑$70s. According to the disclosure, these sales were made solely to cover tax withholding obligations under a “sell to cover” arrangement and were not discretionary.
After these transactions, Feeley beneficially owned 27,148 shares of Class A Common Stock and also held RSUs for up to 109,423 shares and options for up to 25,906 shares, all vesting according to their existing schedules.